Moleculin Biotech, Inc. (MBRX) Stock Price & Analysis
Moleculin Biotech, Inc. (MBRX) fell 2.43% to USD 2.41 as of June 10, 2026 at 03:05 UTC, according to Nexqual real-time market data.
MBRX last closed at USD 2.47; the session ranged USD 2.35–2.49 on volume of 169,360 shares. Market capitalization is $12.86M, with a 52-week range of USD 1.79–24 (NCM). Source: Nexqual, June 10, 2026 at 03:05 UTC.
Key Statistics (as of June 10, 2026 at 03:05 UTC)
| Price | USD 2.41 |
|---|---|
| Change | ▼ 2.43% (down) |
| Previous Close | USD 2.47 |
| Open | USD 2.44 |
| Day Range | USD 2.35 – 2.49 |
| 52-Week Range | USD 1.79 – 24 |
| Volume | 169,360 shares |
| Market Cap | $12.86M |
| Exchange | NCM |
Technical Analysis (MBRX)
Nexqual's technical model rates MBRX "SELL" based on 2 bullish and 4 bearish signals across 124 daily candles, as of June 10, 2026 at 03:05 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 46.9 (neutral) |
| vs SMA50 | Below (USD 2.45) |
| MACD | 0.01 (positive) |
Analyst Ratings (MBRX)
Wall Street analysts rate MBRX "None" based on 3 analysts, with a mean price target of USD 21 (range USD 10–31), per Nexqual as of June 10, 2026 at 03:05 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 21 |
| High Target | USD 31 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (MBRX)
| Revenue Estimate | $0 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -3.54 vs est -1.66 ▼ miss |
| 2025-09-30 | USD -0.68 vs est -6.58 ▲ beat |
| 2025-06-30 | USD -12.25 vs est -10.08 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:05 UTC.
Financials & Fundamentals (MBRX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -532.03% |
| Debt / Equity | 2.15 |
| Current Ratio | 1.38 |
| Total Cash | $10.32M |
| Total Debt | $326,000 |
| Free Cash Flow | $-13.15M |
Source: Nexqual, June 10, 2026 at 03:05 UTC.
Financial Health Score (MBRX)
Nexqual rates Moleculin Biotech, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:05 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $10M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$24M |
| Efficiency | Critical — ROE -532%, ROA -76.1% |
Ownership (MBRX)
| Insider Ownership | +0.83% |
|---|---|
| Institutional Ownership | +4.40% |
| Shares Outstanding | 5.34M |
| Float | 5.29M |
| Short % of Float | +15.67% |
Source: Nexqual, June 10, 2026 at 03:05 UTC.
Leadership (MBRX)
Moleculin Biotech, Inc. is led by Walter V. Klemp (age 65), Co-Founder, Chairman, President & CEO, per Nexqual as of June 10, 2026 at 03:05 UTC.
| Co-Founder, Chairman, President & CEO | Walter V. Klemp (age 65) |
|---|---|
| Executive VP & CFO | Jonathan P. Foster (age 61) |
| Chief Scientific Officer | Donald H. Picker (age 79) |
| Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board | Waldemar Priebe |
Major Backers & Investors (MBRX)
Notable institutional backers of Moleculin Biotech, Inc. include Sabby Management, LLC, Fidelity, HRT Financial LP, according to Nexqual as of June 10, 2026 at 03:05 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Sabby Management, LLC | 1.41% |
| Fidelity | 0.57% |
| HRT Financial LP | 0.26% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.63% |
| Geode Capital | 0.61% |
Source: Nexqual, June 10, 2026 at 03:05 UTC.
From Moleculin Biotech, Inc.'s Latest SEC 10-K Filing (filed 2026-03-18)
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CAPR | Capricor Therapeutics, Inc. | USD 26.01 | ▼ 2.62% |
| PULM | Pulmatrix, Inc. | USD 1.38 | ▲ 3.76% |
| CFOR | OpGen, Inc. | USD 0.5 | ▲ 0% |
| AYTU | Aytu BioPharma, Inc. | USD 2.3 | ▲ 2.22% |
| SNGX | Soligenix, Inc. | USD 0.43 | ▼ 2.95% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:05 UTC. This page is informational and not investment advice.